Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection

NCT04349098 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT04349098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04349098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
April 17, 2020
Completion date
October 5, 2020
Enrollment
190 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection